CV THERAPEUTICS

CV Therapeutics, Inc. operates as a research-based biopharmaceutical company. The Company researches and manufactures drugs for the treatment of cardiovascular disease and more specifically angina pectoris. CV Therapeutics serves the healthcare industry in the United States. CV Therapeutics developed Ranexa, a drug to treat chronic angina; and Lexiscan, an injection used as a stress agent in cardiovascular procedures. The company was acquired by Gilead Sciences, the maker of H.I.V. drugs Truvada, Viread, and Atriplia, for about $1.4 billion.